CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features

Bisig, Bettina; Reyniès, Aurélien de; Bonnet, Christophe; Sujobert, Pierre; Rickman, David S.; Marafioti, T; Delsol, Georges; Lamant, Laurence; Gaulard, Philippe; Leval, Laurence de

doi:10.3324/haematol.2012.081935

Cited by 59 publications

(62 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Molecularly, these cases showed GEP features as indistinguishable from the group that had a concordant pathological diagnosis. There are 2 recent reports on CD301PTCL-NOS, 33,34 and some of these cases may overlap with ALK(-)ALCL defined by our study. Interestingly, the clinical outcome of the molecularly defined ALK(-)ALCL patients was poorer compared with the other PTCL-NOS cases (P 5 .01, data not shown); however, a larger number of cases need to be studied prospectively to confirm this finding.…”

Section: Genome-wide Molecular Profiling Of Aggressive T-cell Lymphomsupporting

confidence: 51%

Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma

Iqbal

Wright

Wang

et al. 2014

Blood

445

409

View full text Add to dashboard Cite

• Diagnostic signatures for PTCL subtypes and 2 novel subgroups with distinct oncogenic pathway and prognostic importance in PTCL-NOS were identified. • Demonstrated that ALK(-) ALCL is a distinct molecular entity and the tumor microenvironment has prognostic significance in AITL patients.Peripheral T-cell lymphoma (PTCL) encompasses a heterogeneous group of neoplasms with generally poor clinical outcome. Currently 50% of PTCL cases are not classifiable: PTCL-not otherwise specified (NOS). Gene-expression profiles on 372 PTCL cases were analyzed and robust molecular classifiers and oncogenic pathways that reflect the pathobiology of tumor cells and their microenvironment were identified for major PTCL-entities, including 114 angioimmunoblastic T-cell lymphoma (AITL), 31 anaplastic lymphoma kinase (ALK)-positive and 48 ALK-negative anaplastic large cell lymphoma, 14 adult T-cell leukemia/lymphoma and 44 extranodal NK/T-cell lymphoma that were further separated into NK-cell and gdT-cell lymphomas. Thirty-seven percent of morphologically diagnosed PTCL-NOS cases were reclassified into other specific subtypes by molecular signatures. Reexamination, immunohistochemistry, and IDH2 mutation analysis in reclassified cases supported the validity of the reclassification. Two major molecular subgroups can be identified in the remaining PTCL-NOS cases characterized by high expression of either GATA3 (33%; 40/121) or TBX21 (49%; 59/121). The GATA3 subgroup was significantly associated with poor overall survival (P 5 .01). High expression of cytotoxic genesignature within the TBX21 subgroup also showed poor clinical outcome (P 5 .05). In AITL, high expression of several signatures associated with the tumor microenvironment was significantly associated with outcome. A combined prognostic score was predictive of survival in an independent cohort (P 5

show abstract

Section: Genome-wide Molecular Profiling Of Aggressive T-cell Lymphomsupporting

confidence: 51%

Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma

Iqbal

Wright

Wang

et al. 2014

Blood

445

409

View full text Add to dashboard Cite

show abstract

“…The expression of these genes is similar between CD30 19 The real prognostic significance of CD30 expression, however, still remains to be confirmed.…”

Section: Introductionmentioning

confidence: 95%

Peripheral T-cell lymphoma, not otherwise specified

Broccoli

Zinzani

2017

Blood

View full text Add to dashboard Cite

Peripheral T-cell lymphoma, not otherwise specified, is a broad category of biologically and clinically heterogeneous diseases that cannot be further classified into any other of the existing entities defined by the World Health Organization classification. Anthracycline-containing regimens, namely cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), nowadays represent the standard first-line treatment; for patients who achieve a satisfactory response, a consolidation by means of autologous stem cell transplantation may offer a greater chance of long-term survival. Several patients, however, display treatment refractoriness or relapse soon after obtaining a response, and just a few of them are suitable transplant candidates. This is why several new agents, with innovative mechanisms of action, have been investigated in this context: pralatrexate, romidepsin, belinostat, and brentuximab vedotin have been approved for relapsed and refractory peripheral T-cell lymphomas based on their activity, although they do not significantly affect survival rates. The incorporation of such new drugs within a CHOP backbone is under investigation to enhance response rates, allow a higher proportion of patients to be transplanted in remission, and prolong survival.

show abstract

“…Some groups have been able to discriminate between PTCL, NOS, and ALCL, ALK À (52); a three-gene model, comprising TNFRSF8, BATF3, and TMOD1 was reported to distinguish between PTCL, NOS, and ALCL, ALK À (53). However, others showed overlapping profiles between PTCL, NOS CD30 þ , and ALCL, ALK À except for higher levels of pSTAT3 in the latter entity (54). Next-generation sequencing analysis has identified a recurrent balanced translocation t(6;7)(p25.3;q32.3) in 10% of ALCL, ALK À , leading to the juxtaposition of the DUSP22 phosphatase gene on chromosome 6p25.3 with the fragile site FRA7H on 7q32.3, resulting in the downregulation of DUSP22 and upregulation of MIR29 microRNAs located on 7q32.3 (29).…”

Section: Angioimmunoblastic T-cell Lymphomamentioning

confidence: 99%

Changing the Paradigms of Treatment in Peripheral T-cell Lymphoma: From Biology to Clinical Practice

O’Connor

Bhagat

Ganapathi

et al. 2014

Clinical Cancer Research

View full text Add to dashboard Cite

Despite enormous advances in our understanding of aggressive lymphomas, it is clear that progress in the peripheral T-cell lymphomas (PTCL) has lagged well behind other B-cell malignancies. Although there are many reasons for this, the one commonly cited notes that the paradigms for diffuse large B-cell lymphoma (DLBCL) were merely applied to all patients with PTCL, the classic "one-size-fits-all" approach. Despite these challenges, progress is being made. Recently, the FDA has approved four drugs for patients with relapsed/refractory PTCL over the past 5 years, and if one counts the recent Japanese approval of the anti-CCR4 monoclonal antibody for patients with adult T-cell leukemia/ lymphoma, five drugs have been approved worldwide. These efforts have led to the initiation of no fewer than four randomized clinical studies exploring the integration of these new agents into standard CHOP (cyclophosphamide-Adriamycin-vincristine-prednisone)-based chemotherapy regimens for patients with newly diagnosed PTCL. In addition, a new wave of studies are exploring the merits of novel drug combinations in the disease, an effort to build on the obvious single-agent successes. What has emerged most recently is the recognition that the PTCL may be a disease-characterized by epigenetic dysregulation, which may help explain its sensitivity to histone deacetylase (HDAC) inhibitors, and open the door for even more creative combination approaches. Nonetheless, advances made over a relatively short period of time are changing how we now view these diseases and, hopefully, have poised us to finally improve its prognosis.

show abstract

CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features

Cited by 59 publications

References 61 publications

Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma

Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma

Peripheral T-cell lymphoma, not otherwise specified

Changing the Paradigms of Treatment in Peripheral T-cell Lymphoma: From Biology to Clinical Practice

Contact Info

Product

Resources

About